Results 41 to 50 of about 2,425 (160)

Integrating Traditional Wisdom With Modern Science: Ginsenosides as Antiheart Failure Agents

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Heart failure (HF), as the terminal stage of various cardiovascular diseases, remains a global health challenge with persistently high morbidity and mortality rates. Although current therapies—including angiotensin receptor–neprilysin inhibitors, sodium‐glucose cotransporter‐2 inhibitors, and cardiac resynchronization therapy—have improved outcomes ...
Li Zhou, Yanhua Li, Wenjie Yin, Xi Gu, Jiana Shi, Fan Yang, Satabdi Datta Choudhury   +6 more
wiley   +1 more source

Fosinopril – characteristics and use

, 2011
ACE-inhibitori mogu se razlikovati prema učinkovitosti, lipofilnosti, putevima eliminacije i vremenu poluizlučivanja, a također i prema osobitosti je li lijek aktivan sastojak ili zahtijeva metaboličku aktivaciju.
Delić-Brkljačić, Diana
core   +1 more source

Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinicofunctional status and quality of life in patients with postinfarction left ventricular dysfunction

Терапевтический архив, 2004
Aim. To study effects ofcarvedilol and atenolol and their combination with fosinopril on heart rhythm variability (HRV), clinicofimctional status and quality of life in postmyocardial infarction patients with moderate chronic cardiac failure (CCF ...
А Т Teplyakov, S V Popov, V V Kalyuzhin, A A Garganeeva, I O Kurlov, V L Nilogov, E V Rybalchenko, S N Shilov   +7 more
doaj  

Evaluation of the influence of the therapy with fosinopril and zofenopril on the regulatory-adaptive status of patients with diastolic chronic heart failure

КардиоСоматика, 2019
Aim. Еvaluate the influence of combination therapy with fosinopril or zofenopril on the regulatory-adaptive status (RAS) of patients with diastolic chronic heart failure (CHF). Material and methods. The study includes 80 patients with CHF I-II functional
Svetlana N. Nedvetskaya, Vitalii G. Tregubov, Iosif Z. Shubitidze, Vladimir M. Pokrovskiy   +3 more
doaj   +1 more source

ANTIHYPERTENSIVE AND VASOPROTECTIVE EFFECTS OF FOSINOPRILE IN PATIENTS WITH ARTERIAL HYPERTENSION

Медицинский совет, 2018
Objective: evaluate antihypertensive and vasoprotective effects of fosinopril in patients with arterial hypertension with a high and very high risk of cardiovascular complications. Material and methods.
N. Yu. Grigorieva, A. N. Kuznetsov, M. E. Koroleva, T. V. Koroleva, O. E. Vilkova   +4 more
doaj   +1 more source

Synthesis of Diaryl‐ and Dialkynylphosphinates From Ubiquitous PV Sources via a Redox‐Neutral Approach

Advanced Science, Volume 12, Issue 36, September 25, 2025.
Classical strategies for P─C bond formation rely on precursors (e.g., PH3, H2PO2, PCl3) obtained from P4, which is produced via the energy‐intensive thermal process. Here, an alternative, redox‐neutral approach is explored. Primary phosphate sources are activated with triflic anhydride (Tf2O) and 4‐dimethylaminopyridine (DMAP) to a versatile PV ...
Tobias Schneider, Kai Schwedtmann, Jannis Fidelius, Rosa M. Gomila, Antonio Frontera, Jan J. Weigand   +5 more
wiley   +1 more source

Fosinopril reduces left ventricular mass in untreated hypertensive patients: A controlled trial

, 1999
Aims. Left ventricular hypertrophy is a powerful predictor of cardiovascular morbidity and mortality. We tested the hypothesis that fosinopril, an angiotensin-converting enzyme inhibitor, reduces left Ventricular mass in hypertensive patients.
Lau, CP, Cheung, BMY
core   +1 more source

Evaluating chronopharmacological effectiveness of fosinopril and its combination with melatonin in elderly patients with hypertension and coronary artery disease

Медицинский совет, 2014
High incidence of cardiovascular diseases globally, including arterial hypertension (AH) and coronary artery disease (CAD), as well as a considerable social impact made by the diseases and their complications, call for finding new ways to improve ...
O. A. Lednev
doaj   +1 more source

Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives [PDF]

, 1990
Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Hypertension and renal mass reduction induce glomerular hypertension (GH), hyperfiltration (HF) and renal injury.
Pérez-Grovas, Héctor, Herrera-Acosta, Jaime, Ron, Oscar, Bochicchio, Tommaso, Sandoval, Guadalupe, Bordes, Javier   +5 more
core   +1 more source

The role of fosinopril in the treatment and prevention of cardiovascular diseases

Медицинский совет, 2015
In Russia, cardiovascular diseases account for 57% of deaths in the overall mortality. Arterial hypertension (AH) is one of the main risk factors (RF) for cardiovascular diseases (along with dyslipidemia, smoking, metabolic syndrome, diabetes mellitus ...
G. A. Baryshnikova
doaj   +1 more source